
浏览全部资源
扫码关注微信
400038 重庆,陆军军医大学(第三军医大学)军事预防医学系军队营养与食品安全研究中心,重庆市医学营养研究中心,重庆市营养与食品安全重点实验室
[易龙, E-mail: longgyin8341@hotmail.com YI Long, E-mail: longgyin8341@hotmail.com
收稿:2022-06-29,
修回:2022-08-18,
纸质出版:2023-01-30
移动端阅览
蒋玲, 李鹏飞, 候鹏飞, 等. 二氢杨梅素对代谢相关脂肪性肝病小鼠结肠黏膜屏障功能改善作用研究[J]. 陆军军医大学学报, 2023,45(2):146-154.
Ling JIANG, Pengfei LI, Pengfei HOU, et al. Dihydromyricetin improves colonic mucosal barrier function in mice with metabolism-associated fatty liver disease[J]. Journal of Army Medical University, 2023, 45(2): 146-154.
蒋玲, 李鹏飞, 候鹏飞, 等. 二氢杨梅素对代谢相关脂肪性肝病小鼠结肠黏膜屏障功能改善作用研究[J]. 陆军军医大学学报, 2023,45(2):146-154. DOI: 10.16016/j.2097-0927.202206187.
Ling JIANG, Pengfei LI, Pengfei HOU, et al. Dihydromyricetin improves colonic mucosal barrier function in mice with metabolism-associated fatty liver disease[J]. Journal of Army Medical University, 2023, 45(2): 146-154. DOI: 10.16016/j.2097-0927.202206187.
目的
2
研究二氢杨梅素(dihydromyricetin
DHM)对代谢相关脂肪性肝病(metabolic-associated fatty liver disease
MAFLD)的改善作用
并揭示其调节肠黏膜屏障功能的作用机制。
方法
2
32只雄性C57BL/6J小鼠随机分为4组(
n
=8): CON (对照
脂肪供能比为10%饮食)组、高脂饮食(HFD
脂肪供能比为45%)组、HFD+DHM组(添加质量比0.6% DHM的高脂饲料)和DHM组(添加质量比0.6% DHM的对照饲料)
干预12周。每周测量小鼠体质量、摄食量; 处死前进行空腹血糖、葡萄糖耐量和肠道通透性检测; 试剂盒检测血清生化指标、脂多糖(LPS); 肝组织进行油红O染色和HE染色
观察组织病理学变化; RT-qPCR和Western blot法检测肠上皮紧密连接蛋白、抗菌肽及肝脏炎症因子表达水平; 流式细胞术检测结肠3型固有淋巴样细胞(group 3 innate lymphoid cells
ILC3)比例以及IL-22表达水平。
结果
2
与CON组比较
HFD组小鼠体质量增加
糖耐量受损
血清总胆固醇、甘油三酯、谷丙转氨酶、谷草转氨酶升高
肝脏脂质沉积和炎性因子
IL
-1
β
、
IL
-6、
TNF
-
α
mRNA表达水平升高
肠道通透性和血清LPS增加
肠黏膜紧密连接蛋白
ZO
-1、
Occludin
及抗菌肽
Reg
Ⅲ
β
、
Reg
Ⅲ
γ
表达水平降低
结肠ILC3及IL-22
+
ILC3比例降低(
P
<
0.05)。与HFD组比较
HFD+DHM组糖耐量受损明显改善
肝脏脂质沉积和炎性因子表达减少
血清LPS水平降低
肠紧密连接蛋白和抗菌肽表达水平增加
肠道通透性减少
结肠ILC3和IL-22
+
ILC3比例增加(
P
<
0.05)。
结论
2
DHM可能通过改善肠黏膜屏障功能减少肝脏脂质堆积和炎症反应
改善MAFLD疾病进程。
Objective
2
To investigate the ameliorative effects of dihydromyricetin (DHM) on metabolism-associated fatty liver disease (MAFLD)
and to reveal the mechanism of its regulation of intestinal mucosal barrier function.
Methods
2
Thirty-two male C57BL/6J mice were randomly divided into 4 groups (
n
=8): CON (control diet
with 10% fat) group
HFD (high-fat diet
with 45% fat) group
HFD+DHM (high-fat diet+0.6% DHM) group
and DHM (control diet+0.6% DHM) gro
up.All the subjects were intervened for 12 weeks
the body weight and food consumption of mice were measured weekly.Fasting blood glucose
glucose tolerance and intestinal permeability were tested before sacrifice.Serum levels of biochemical indexes and lipopolysaccharide (LPS) were detected with corresponding kits.The liver tissues were stained with HE and oil red O staining
respectively
and the histopathological changes were observed.Moreover
RT-qPCR and Western blotting were used to measure the expression levels of intestinal epithelial tight junction proteins
antimicrobial peptides and liver inflammatory factors.Flow cytometry was adopted to determine the proportion of group 3 innate lymphoid cells (ILC3) and the level of IL-22 in the colon.
Results
2
As compared with the CON group
the HFD group presented increased body weight
impaired glucose tolerance
as well as elevated serum total cholesterol
triglyceride
alanine transaminase and aspartate transaminase.HFD also led to liver lipid deposition and higher mRNA levels of
IL
-1
β
IL
-6 and
TNF
-
α
in the liver.The intestinal permeability and serum LPS were increased
whereas the expression levels of tight junction proteins
ZO
-1 and
Occludin
and antimicrobial peptides
Reg
Ⅲ
β
and
Reg
Ⅲ
γ
in the intestinal mucosa were decreased
and the proportions of ILC3 and IL-22
+
ILC3 in the colon were declined (
P
<
0.05).In the HFD+DHM group
the impaired glucose tolerance was significantly improved
the hepatic lipid deposition and the expression of inflammatory factors were reduced
so was the serum LPS level.DHM also upregulated the levels of intestinal tight junction proteins and antimicrobial peptides
and ameliorated the intestinal permeability.Furthermore
the colonic ILC3 and IL-22
+
ILC3 ratios were increased b
y DHM treatment as well (
P
<
0.05).
Conclusion
2
DHM may ameliorate the progression of MAFLD by improving intestinal barrier function to reduce lipid accumulation and inflammatory responses in the liver.
ESLAM M, SANYAL A J, GEORGE J, et al . MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J ] . Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312.
YOUNOSSI Z, ANSTEE Q M, MARIETTI M, et al . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J ] . Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
MOORE M P, CUNNINGHAM R P, DASHEK R J, et al . A fad too far? Dietary strategies for the prevention and treatment of NAFLD[J ] . Obesity (Silver Spring), 2020, 28(10): 1843-1852. DOI: 10.1002/oby.22964.
TONG H H, ZHANG X J, TAN L F, et al . Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases[J ] . Eur J Pharmacol, 2020, 870: 172888. DOI: 10.1016/j.ejphar.2019.172888.
CHEN S H, ZHAO X L, WAN J, et al . Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: a randomized controlled trial[J ] . Pharmacol Res, 2015, 99: 74-81. DOI: 10.1016/j.phrs.2015.05.009.
ZENG X L, YANG J N, HU O, et al . Dihydromyricetin ameliorates nonalcoholic fatty liver disease by improving mitochondrial respiratory capacity and redox homeostasis through modulation of SIRT3 signaling[J ] . Antioxid Redox Signal, 2019, 30(2): 163-183. DOI: 10.1089/ars.2017.7172.
ZHOU X, YU L, ZHOU M, et al . Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect[J ] . Nutr Metab (Lond), 2021, 18(1): 64. DOI: 10.1186/s12986-021-00589-6.
HUANG L, ZENG X L, LI B, et al . Dihydromyricetin attenuates palmitic acid-induced oxidative stress by promoting autophagy via SIRT3-ATG4B signaling in hepato cytes[J ] . Nutr Metab (Lond), 2021, 18(1): 83. DOI: 10.1186/s12986-021-00612-w.
余利, 蒋玲, 周杰, 等. 小鼠肠道3型固有淋巴样细胞检测与分析方法研究[J]. 局解手术学杂志, 2022, 31(2): 113-118.
YU L, JIANG L, ZHOU J, et al . Detection and analysis method of group 3 innate lymphoid cells in miceintestine[J ] . J Reg Anat Oper Surg, 2022, 31(2): 113-118.
ZHOU J H, ZHOU F, WANG W X, et al . Epidemiological features of NAFLD from 1999 to 2018 in China[J ] . Hepatology, 2020, 71(5): 1851-1864. DOI: 10.1002/hep.31150.
ESTES C, ANSTEE Q M, ARIAS-LOSTE M T, et al . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J ] . J Hepatol, 2018, 69(4): 896-904. DOI: 10.1016/j.jhep.2018.05.036.
BUZZETTI E, PINZANI M, TSOCHATZIS E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.
LI X Y, WANG H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease[J]. Cell Biosci, 2020, 10(1): 140. DOI: 10.1186/s13578-020-00507-y.
ZHANG X, JI X T, WANG Q, et al . New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J ] . Protein Cell, 2018, 9(2): 164-177. DOI: 10.1007/s13238-017-0436-0.
GHOSH S S, HE H L, WANG J, et al . Curcumin-mediated regulation of intestinal barrier function: the mechanism underlying its beneficial effects[J ] . Tissue Barriers, 2018, 6(1): e1425085. DOI: 10.1080/21688370.2018.1425085.
ZHANG X Y, CHEN J, YI K, et al . Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity[J ] . Gut Microbes, 2020, 12(1): 1-18. DOI: 10.1080/19490976.2020.1842990.
DONG S J, ZHU M, WANG K, et al . Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism[J ] . Pharmacol Res, 2021, 171: 105767. DOI: 10.1016/j.phrs.2021.105767.
GOTO Y, OBATA T, KUNISAWA J, et al . Innate lymphoid cells regulate intestinal epithelial cell glycosylation[J ] . Science, 2014, 345(6202): 1254009. DOI: 10.1126/science.1254009.
ZELANTE T, IANNITTI R G, CUNHA C, et al . Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22[J ] . Immunity, 2013, 39(2): 372-385. DOI: 10.1016/j.immuni.2013.08.003.
PATNAUDE L, MAYO M, MARIO R, et al . Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair[J ] . Life Sci, 2021, 271: 119195. DOI: 10.1016/j.lfs.2021.119195.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621